Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

被引：89

作者：

Allen, LF

Lenehan, PF

Eiseman, IA

Elliott, WL

Fry, DW

机构：

[1] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Clin Dev, Ann Arbor, MI 48105 USA

[2] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Oncol, Ann Arbor, MI 48105 USA

[3] Pfizer Global Res & Dev, Ann Arbor Labs, Dept Canc Pharmacol, Ann Arbor, MI 48105 USA

来源：

关键词：

D O I：

10.1053/sonc.2002.34049

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：11 / 21

页数：11

共 115 条

[1] GROWTH-FACTORS AND CANCER
AARONSON, SA
[J]. SCIENCE, 1991, 254 (5035) : 1146 - 1153
[2] ALIMANDI M, 1995, ONCOGENE, V10, P1813
[3] BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13
[4] Cyclin D1 in breast cancer
Barnes, DM
Gillett, CE
[J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 1 - 15
[5] Baselga J, 1999, SEMIN ONCOL, V26, P78
[6] Baselga J, 1998, CANCER RES, V58, P2825
[7] Bodey B, 1997, ANTICANCER RES, V17, P1319
[8] c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells
Brandt, BH
Roetger, A
Dittmar, T
Nikolai, G
Seeling, M
Merschjann, A
Nofer, JR
Dehmer-Möller, G
Junker, R
Assmann, G
Zaenker, KS
[J]. FASEB JOURNAL, 1999, 13 (14) : 1939 - 1949
[9] Bucci B, 1997, ANTICANCER RES, V17, P769
[10] A NEU ACQUAINTANCE FOR ERBB3 AND ERBB4 - A ROLE FOR RECEPTOR HETERODIMERIZATION IN GROWTH SIGNALING
CARRAWAY, KL
CANTLEY, LC
[J]. CELL, 1994, 78 (01) : 5 - 8